The NHIF database contains information on the prescribed and dispensed drug name, date of prescription and dispensing, International Classification of Diseases (ICD-10) diagnosis codes, anatomical-therapeutic-chemical (ATC) code of the drug, number of packs dispensed, number of tablets in each ...
Pruritus is a common adverse effect that limits the use of OCA in some patients, but the medication is otherwise generally well-tolerated [13]. Fibrates also have an off-label indication for treatment of PBC given their anticholestatic properties [14]. At present, alternative therapies are only...
The primary outcome was all-cause death, and secondary outcome was a major adverse cardiac event (MACE), a composite of: all-cause death, ACS admission (ICD-10-AM I20.0 or I21 in the principal diagnosis field), stroke admission (ICD-10-AM I60, I61, I63, I64 in the principal ...
theICD. Intellectual disability was defined as having at least 1 inpatient or outpatient specialist care admission between birth and the end of follow-up at December 31, 2014, with anICD-10code of F70 to F79. Supplemental analyses were conducted for mild to moderate ID usingICD-10codes of ...
Comorbidity influences screening practice, treatment choice, quality of life, and survival. The presence of comorbidities and medication use could place patients at greater risks of adverse effects f...
Adverse drug events are responsible for up to 7% of all admissions to acute care hospitals. At least 58% of these are preventable, resulting from incomplete drug information, prescribing or dispensing errors, and overuse or underuse of medications. Effec
(e.g. disease diagnosis) for taking medication were not recorded. The duration, dosage, response and adverse effect of medications were not recorded. For this reason we could not conduct pharmacogenomics analyses to identify associations of SNPs with treatment response or dosage level. Third, our ...
frailty syndrome. The median of the average result of TFI was significantly higher in the low adherence group (p˂ 0.001) (Mdn = 9, Q1–Q3; 7–10 pt.) than in the medium (Mdn = 6, Q1–Q3; 5–9 pt.) or high adherence (Mdn = 6.00, Q1–Q3; 4.5–8 pt.) ones. The ...
The effect can enhance or reduce the drugs’ efficacy and reduce or aggravate the side effects. For example, the combination of a cholinesterase reactivator and atropine sulfate can produce complementary effects, which reduces the amount of atropine and adverse effects. The antimalarial drug ...
In the population under study, almost 29% received least one non-cardiac drug with this potential adverse drug effect. The prevalence estimate is influenced by the population studied and the drugs included. Comparison with other studies is hampered by differences in the study population and numbers...